EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Pharmacological translation of cancer missense mutations for therapeutic targeting with small molecules

Mariam Fouad

Biochemical Pharmacology · 2026

DOI: 10.1016/j.bcp.2026.118508 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von Mariam Fouad. Beteiligte Einrichtung: Tumor Signaling and Microenvironment Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, United States. Electronic address:…. Hauptthemen laut MEDLINE: Mutation, Missense, Neoplasms, Antineoplastic Agents, Small Molecule Libraries. Die Arbeit nennt 83 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted therapies built around specific genetic driver mutations have become a cornerstone of precision oncology. These mutations, often found in oncogenes such as Kirsten rat sarcoma (KRAS) or tumor suppressors such as TP53, contribute to tumor initiation, progression, and therapeutic resistance. Recent successes with KRAS inhibitors targeting G12C and G12D mutations highlight the clinical potential of mutation-specific drug design. Concurrently, advances in machine learning have enhanced predictions of missense variant effects by integrating amino acid dynamics, structural perturbations, and pathogenicity scores. This review synthesizes current computational tools and emerging therapeutic small-molecule inhibitors, protein degraders, and proximity-based therapeutics to provide a comprehensive framework that links structure-function relationships to the rational design of next-generation cancer treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mutation, MissenseNeoplasmsAntineoplastic AgentsSmall Molecule LibrariesTranslational Research, BiomedicalHumansAnimalsProto-Oncogene Proteins p21(ras)Molecular Targeted Therapy

Stichwörter der Autor:innen

Amino acid substitutionComputational predictionSecondary mutationStructure conformationStructure–activity relationshipTyrosine kinase inhibitor

Substanzen

Antineoplastic AgentsSmall Molecule LibrariesProto-Oncogene Proteins p21(ras)

Autor:innen und Institutionen

  • Tumor Signaling and Microenvironment Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, United States. Electronic address: Fouadhafez.mar@gmail.com.

Zitieren

APA

Fouad, M. (2026). Pharmacological translation of cancer missense mutations for therapeutic targeting with small molecules. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.118508

Vancouver

Fouad M. Pharmacological translation of cancer missense mutations for therapeutic targeting with small molecules. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.118508

BibTeX
@article{Fouad2026,
  author = {Fouad, Mariam},
  title = {Pharmacological translation of cancer missense mutations for therapeutic targeting with small molecules},
  journal = {Biochemical Pharmacology},
  year = {2026},
  doi = {10.1016/j.bcp.2026.118508}
}
Kostenlos starten →